oxfordbiodynamics, Author at Oxford Biodynamics

Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment

by oxfordbiodynamics

Board restructure to support future growth

by oxfordbiodynamics

Oxford BioDynamics to present at BioTech Pharma Summit: Liquid Biopsy 2020 in Lisbon, Portugal

by oxfordbiodynamics

Oxford Biodynamics Plc enters into master service agreement

by oxfordbiodynamics

Final Results for year ended 30 September 2019

by oxfordbiodynamics

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling

by oxfordbiodynamics

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling

by oxfordbiodynamics

Oxford BioDynamics’ EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

Journal articles P142 and P143

Links to top articles -

Associated Press

by oxfordbiodynamics

OBD to appoint Professor Iain McInnes to its Scientific Advisory Board

by oxfordbiodynamics

Oxford BioDynamics notes first patient enrolled in ALS biomarker study sponsored by Mitsubishi Tanabe Pharma America

by oxfordbiodynamics